ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
insight
/
details

Unlocking Therapeutic Avenues: Targeted Drugs Tailored to Genetic Drivers in LungCancer

NextEdge Admin

01 Jan 2024

2 min 30 sec

EGFR (Epidermal Growth Factor Receptor) Mutations:

Targeted Therapy: Gefitinib, Erlotinib, Afatinib, Osimertinib.

ALK (Anaplastic Lymphoma Kinase) Rearrangements:

Targeted Therapy: Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib.

ROS1 (ROS Proto-Oncogene 1) Rearrangements:

Targeted Therapy: Crizotinib, Ceritinib, Entrectinib.

KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) Mutations:

Therapeutic Approaches: Direct targeting of KRAS has historically been challenging, but efforts are ongoing. Other strategies involve combination therapies, such as MEK inhibitors like Trametinib.

BRAF (V-Raf Murine Sarcoma Viral Oncogene Homolog B) Mutations:

Targeted Therapy: Dabrafenib (BRAF inhibitor) in combination with Trametinib (MEK inhibitor).

HER2 (Human Epidermal Growth Factor Receptor 2) Mutations:

Targeted Therapy: Currently, HER2-targeted therapies such as Trastuzumab and Pertuzumab are more established in breast cancer. Research is ongoing to explore their role in lung cancer with HER2 mutations.

RET (Rearranged During Transfection) Rearrangements:

Targeted Therapy: Selpercatinib, Pralsetinib.

NTRK (Neurotrophic Receptor Tyrosine Kinase) Fusions:

Targeted Therapy: Larotrectinib, Entrectinib.

c-MET Dysregulation:

Targeted Therapy: Crizotinib, Capmatinib, Tepotinib.

PD-L1 Expression in Lung Cancer:

Immune Checkpoint Inhibitors: Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab. These drugs do not target mutations directly but instead block the PD-1/PD-L1 interaction to enhance the immune response against cancer cells.

It’s important to note that the landscape of targeted therapies and immunotherapies is continually evolving, with ongoing research and the development of new drugs and treatment strategies. Clinical decisions regarding treatment should be made in consultation with healthcare professionals based on the latest information and individual patient characteristics.